{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","spread":"31.39","value":"1368.11"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG005","spread":"NA","value":"1891.48"},{"groupId":"OG007","spread":"22.85","value":"3048.33"},{"groupId":"OG008","spread":"68.31","value":"3297.95"},{"groupId":"OG009","spread":"40.63","value":"3174.42"},{"groupId":"OG012","spread":"39.76","value":"3432.89"},{"groupId":"OG013","spread":"52.33","value":"2901.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"15"},{"groupId":"OG014","value":"0"}],"units":"Participants"}],"title":"AUC(0-24), n=0,0,0,5,0,1,0,15, 2,8,0,0,6,15,0"},{"categories":[{"measurements":[{"groupId":"OG003","spread":"28.96","value":"1691.75"},{"comment":"Geometric coefficient of variation could not be calculated for a single participant","groupId":"OG005","spread":"NA","value":"2013.33"},{"groupId":"OG007","spread":"28.50","value":"3684.96"},{"groupId":"OG008","spread":"72.79","value":"4499.65"},{"groupId":"OG009","spread":"42.09","value":"4003.48"},{"groupId":"OG012","spread":"41.20","value":"3908.15"},{"groupId":"OG013","spread":"48.39","value":"4714.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"10"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"7"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"7"},{"groupId":"OG014","value":"0"}],"units":"Participants"}],"title":"AUC(0-inf), n=0,0,0,5,0,1,0,10, 2,7,0,0,6,7,0"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"8"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"15"},{"groupId":"OG014","value":"0"}],"units":"Participants"}],"description":"Plasma samples for PK analysis of GSK3529246 (active metabolite) were collected at the indicated time points. PK parameters were calculated by standard non-compartmental analysis. GSK3529246 is a metabolite of GSK525762.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.","id":"OG000","title":"Part 1: GSK525762 5 mg QD"},{"description":"Participants were administered once daily oral dose of 10 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 10 mg QD"},{"description":"Participants were administered once daily oral dose of 20 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 20 mg QD"},{"description":"Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.","id":"OG003","title":"Part 1: GSK525762 30 mg QD MM"},{"description":"Participants were administered once daily oral dose of 40 mg GSK525762.","id":"OG004","title":"Part 1: GSK525762 40 mg QD"},{"description":"Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.","id":"OG005","title":"Part 1: GSK525762 40 mg QD MM"},{"description":"Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.","id":"OG006","title":"Part 1: GSK525762 60 mg QD AML"},{"description":"Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG007","title":"Part 1: GSK525762 60 mg QD NHL"},{"description":"Participants with MM were administered once daily oral dose of 60 mg GSK525762.","id":"OG008","title":"Part 1: GSK525762 60 mg QD MM"},{"description":"Participants with AML were administered once daily oral dose of 75 mg GSK525762.","id":"OG009","title":"Part 1: GSK525762 75 mg QD AML"},{"description":"Participants were administered once daily oral dose of 80 mg GSK525762.","id":"OG010","title":"Part 1: GSK525762 80 mg QD"},{"description":"Participants with AML were administered once daily oral dose of 80 mg GSK525762.","id":"OG011","title":"Part 1: GSK525762 80 mg QD AML"},{"description":"Participants with NHL were administered once daily oral dose of 80 mg GSK525762.","id":"OG012","title":"Part 1: GSK525762 80 mg QD NHL"},{"description":"Participants with AML were administered once daily oral dose of 100 mg GSK525762.","id":"OG013","title":"Part 1: GSK525762 100 mg QD AML"},{"description":"Participants with AML were administered once daily oral dose of 120 mg GSK525762.","id":"OG014","title":"Part 1: GSK525762 120 mg QD AML"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles). Plasma samples were not collected for analysis of GSK3529246 (active metabolite) for cohort GSK525762 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD AML, 80 mg QD, 80 mg QD AML, 120 mg QD AML.","reportingStatus":"POSTED","timeFrame":"Week 1 Day 1: pre-dose and at 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours post-dose","title":"Part 1: AUC(0-24) and AUC[0-inf] of GSK3529246 (Active Metabolite) Following Single Dose Administration","type":"SECONDARY","unitOfMeasure":"Hours*nanograms per milliliter"}